Problem:Brain diseases are leading causes of death and disability, including: traumatic brain Injury (TBI), multiple sclerosis (MS), post-traumatic epilepsy (PTE), Alzheimer's disease and related dementias (ADRD), and chronic traumatic encephalopathy (CTE). Only 2 of 200+ FDA-approved central nervous system (CNS) drugs are large molecules such as monoclonal antibodies (mAbs) due to their poor penetrance of the blood-brain barrier (BBB) (e.g., 0.1-1.0%). In contrast, mAbs are the most successful therapeutics globally, comprising 7 of 10 best-selling drugs in 2017 with 182+ mAbs in clinical trials for non-CNS indications in 2019.
Solution: Gryphon Bio is a preclinical-stage therapeutic bioconjugate company created to harness our co-founders' discovery of novel therapeutic targets and temporal biomarkers in unexpected waves of brain molecules in the blood for rush delivery of medicines to the brain.
Mission: To develop and market the first therapeutic bioconjugate to accelerate brain repair and improve cognition.
Vision: To pioneer therapeutic bioconjugates as safe and efficacious brain medicines to improve the lives of patients.